PETER GOELZ — Lobbyist Profile | Poliscope

PETER GOELZ

Reported covered position: Legislative Intern - Rep. Erik Paulsen

Filings

Clients

Firms

Years active

2014–2015

Associated filing income

$230,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
ABBVIE	3	2015
LAS VEGAS CONVENTION AND VISITORS AUTHORITY	3	2014–2015

Lobbying firms

Firm	Filings	Years
BROWNSTEIN HYATT FARBER SCHRECK, LLP	6	2014–2015

Bills explicitly cited in this lobbyist’s assigned issues (6)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 1101

Viral Hepatitis Testing Act of 2015

Client: ABBVIE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP

Open original LDA filing ↗

Cited source text

H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Biosimilars FDA Reform 21st Century Cures

H.R. 1101

Viral Hepatitis Testing Act of 2015

Client: ABBVIE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP

Open original LDA filing ↗

Cited source text

H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Biosimilars FDA Reform 21st Century Cures

Original LDA source filings (6)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

ABBVIE via BROWNSTEIN HYATT FARBER SCHRECK, LLP

2015 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ABBVIE via BROWNSTEIN HYATT FARBER SCHRECK, LLP

2015 · third_quarter · Q3

Firm income: $50,000

Source: Senate LDA